Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Atezolizumab with or without Tocilizumab or Etrumadenant in Treating Men with Localized Prostate Cancer before Radical Prostatectomy

Trial Status: active

This phase II trial studies how well atezolizumab works alone or in combination with tocilizumab or etrumadenant in treating men with localized prostate cancer before radical prostatectomy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Tocilizumab is an antibody (a protein similar to those produced by the body's immune system) that binds to a protein called IL-6R. High levels of IL-6 may promote tumor growth. Blocking IL-6R with tocilizumab may reset the immune system to recognize the tumor and help shrink it. Etrumadenant may block the suppression (stopping) of the immune system caused by adenosine (a hormone in your body) and cancer cells. We want to see how effective atezolizumab and tocilizumab or etrumadenant are when used together for people with advanced local prostate cancer.